NATRILIX® indapamide
Prescribing Information
Refer to Summary of Product Characteristics before prescribing.

Presentation: White film-coated tablets each containing 2.5mg indapamide hemihydrate.
Indications: Essential hypertension in adults. Indapamide may be used as sole therapy or combined with other antihypertensive agents. Dosage and administration: Adults: The dosage is one tablet daily, to be taken in the morning. The action of indapamide is progressive and the reduction in blood pressure may continue and not reach a maximum until several months after the start of the therapy. A larger dose than 2.5mg indapamide is not recommended as there is no appreciable additional antihypertensive effect. The co-administration of indapamide with diuretics which may cause hypokalaemia is not recommended. Elderly: Can be treated with indapamide when renal function is normal or only minimally impaired. Paediatric population: The safety and efficacy of indapamide in children and adolescents have not been established. No data available. Contraindications: Hypersensitivity to indapamide, to other sulfonamides or to any of the excipients; severe renal failure; hepatic encephalopathy or severe hepatic impairment; or hypokalaemia. Precautions: In hepatic impairment, if encephalopathy occurs, stop indapamide immediately. If photosensitivity occurs during treatment, stop indapamide. Not to be used in patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Plasma sodium should be measured before and at intervals during treatment. Plasma potassium should be monitored closely from the first week of treatment in patients in whom hypokalaemia presents a risk. Slight, transitory rise in plasma calcium may occur. Gout attacks may increase in hyperuricaemic patients. Reduction in glomerular filtration due to hypovolaemia may worsen renal insufficiency. Pregnancy/Breast-feeding: avoid the use of indapamide. Interactions: Serum lithium concentrations may rise during lithium therapy; combination not recommended. Caution required in co-administration with drugs prolonging QT interval or causing torsades de pointes, NSAIDs including COX-2 selective inhibitors, high-dose salicylate, ACE inhibitors, compounds causing hypokalaemia, baclofen, digitalis. Careful consideration required in co-administration with potassium-sparing diuretics, metformin, iodinated contrast media, imipramine-like antidepressants or neuroleptics, calcium, ciclosporin, tacrolimus and systemic corticosteroids or tetracosactide. Side effects: Hypokalaemia, hypersensitivity reactions, mainly dermatological, in subjects with a predisposition to allergic and asthmatic reactions (e.g. maculopapular rash). Very rarely hypotension, arrhythmias, blood dyscrasias, pancreatitis, renal failure, abnormal hepatic function, angioedema and/or toxic epidermal necrolysis, Stevens-Johnson syndrome, hypercalcaemia. Frequency not known: syncope, torsades de pointes, QT prolongation, hepatitis, elevated liver enzymes, hyponatraemia. Consult SPC for full list of side effects. NHS price: 30 tablet pack £3.40; 60 tablet pack £6.80. Legal category: POM. Product licence number: 00093/0022. Further information: Servier Laboratories Ltd, Rowley, Wexham Springs, Slough SL3 6PJ Tel (01753) 666409. Date of Revision: February 2016.